MAY 21, 2019 11:25 AM PDT

Benralizumab not effective reducing exacerbations of COPD

WRITTEN BY: Nouran Amin

According to the American Lung Association, chronic obstructive pulmonary disease (COPD) is the third leading cause of death in this country. More than often, patients go through potentially life-threatening exacerbations, including days-long flare-ups of symptoms, shortness of breath, swelling and mucus.

Now, a recent study published in the New England Journal of Medicine, shows that a drug used as a therapeutic for asthma, has failed to reduce symptoms of COPD. The drug is called benralizumab and is interleukin-5 receptor alpha-directed cytolytic monoclonal antibody that is FDA approved to treat severe eosinophilic asthma—the presence of high amounts of eosinophils (a particular type of immune cell) exacerbates the symptoms of COPD.

"COPD is a life-altering condition that causes serious long-term disability for patients," said Dr. Criner, Chair and Professor of Thoracic Medicine and Surgery at the Lewis Katz School of Medicine at Temple University, Director of the Temple Lung Center and corresponding author on the study. "Discovering treatments that prevent and/or limit exacerbations is a priority for clinicians and researchers as we seek to improve the quality of life for patients. Unfortunately benralizumab did not accomplish that objective in these studies, but the findings will inform current and future avenues of exploration for new treatments."

However, an earlier phase II trial found that benralizumab had a non-statistically significant reduction in COPD exacerbation rate for patients with eosinophilic inflammation in their airways.

"The findings in these two trials suggest that eosinophil depletion may not completely ameliorate exacerbation outcomes for patients with COPD," added Dr. Criner. "However, as one of the nation's premier lung-disease research centers, the Temple Lung Center continues to investigate alternative treatment options and offer patients access to leading-edge clinical trials."

Source: Temple Health

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
DEC 05, 2019
Health & Medicine
DEC 05, 2019
Once-a-Month Contraceptive Pill Closer to Reality
While a variety of contraceptive options exist, each has its pros and cons. As many women understand, one of the major drawbacks of the daily birth control...
DEC 21, 2019
Drug Discovery & Development
DEC 21, 2019
Magic Mushrooms Pass First Clinical Trial Against Depression
With the efficacy of selective serotonin reuptake inhibitors such as Prozac increasingly coming under question, the search for new pharmaceutical treatment...
DEC 22, 2019
Genetics & Genomics
DEC 22, 2019
New Gene Therapy Uses Exosomes to Reverse Disease
Researchers at Ohio State University have developed a new gene therapy that makes use of exosomes, fluid sacs released in cells, to carry therapeutic tools...
JAN 14, 2020
Drug Discovery & Development
JAN 14, 2020
Promising Treatment for Dementia: Antibiotics
A class of antibiotics, known as the ‘aminoglycosides’ may serve as a promising treatment for frontotemporal dementia—according to resear...
JAN 15, 2020
Drug Discovery & Development
JAN 15, 2020
FDA Approves Drugs Faster than Ever- But is That Good?
The Food and Drug Administration (FDA) is approving new drugs for patients on less and less evidence thanks to special programs that streamline their appro...
JAN 18, 2020
Drug Discovery & Development
JAN 18, 2020
Using Vitamins to Treat Pediatric Sepsis
New research indicates that is very much possible to treat pediatric septic shock in children with a combination of intravenous vitamin C and intravenous v...
Loading Comments...